Although pharmacologic inhibition of the TGF-β pathway has long been explored in glioma, clinical applications have been hampered by systemic toxicity and the pleiotropic, context-dependent nature of TGF-β signaling (59, 60). This evidence concerns the gene TGFB1 and glioma.